CA2647655C - Nouveaux analogues substitues en c-1 de la pancratistatine et de la 7-desoxypancratistatine et leurs procedes de preparation - Google Patents

Nouveaux analogues substitues en c-1 de la pancratistatine et de la 7-desoxypancratistatine et leurs procedes de preparation Download PDF

Info

Publication number
CA2647655C
CA2647655C CA2647655A CA2647655A CA2647655C CA 2647655 C CA2647655 C CA 2647655C CA 2647655 A CA2647655 A CA 2647655A CA 2647655 A CA2647655 A CA 2647655A CA 2647655 C CA2647655 C CA 2647655C
Authority
CA
Canada
Prior art keywords
compound
formula
nr2r3
groups
defined above
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2647655A
Other languages
English (en)
Other versions
CA2647655A1 (fr
Inventor
Tomas Hudlicky
Jonathan Collins
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brock University
Original Assignee
Brock University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brock University filed Critical Brock University
Priority to CA2647655A priority Critical patent/CA2647655C/fr
Publication of CA2647655A1 publication Critical patent/CA2647655A1/fr
Application granted granted Critical
Publication of CA2647655C publication Critical patent/CA2647655C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des composés de la formule I : (voir la formule I) à des compositions pharmaceutiques contenant ces composés et à lutilisation de ces composés dans le traitement du cancer. Lapplication concerne également des procédés pour la préparation de ces composés et la préparation dintermédiaires dans cette préparation.
CA2647655A 2008-12-23 2008-12-23 Nouveaux analogues substitues en c-1 de la pancratistatine et de la 7-desoxypancratistatine et leurs procedes de preparation Active CA2647655C (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA2647655A CA2647655C (fr) 2008-12-23 2008-12-23 Nouveaux analogues substitues en c-1 de la pancratistatine et de la 7-desoxypancratistatine et leurs procedes de preparation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA2647655A CA2647655C (fr) 2008-12-23 2008-12-23 Nouveaux analogues substitues en c-1 de la pancratistatine et de la 7-desoxypancratistatine et leurs procedes de preparation

Publications (2)

Publication Number Publication Date
CA2647655A1 CA2647655A1 (fr) 2010-06-23
CA2647655C true CA2647655C (fr) 2016-12-20

Family

ID=42283103

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2647655A Active CA2647655C (fr) 2008-12-23 2008-12-23 Nouveaux analogues substitues en c-1 de la pancratistatine et de la 7-desoxypancratistatine et leurs procedes de preparation

Country Status (1)

Country Link
CA (1) CA2647655C (fr)

Also Published As

Publication number Publication date
CA2647655A1 (fr) 2010-06-23

Similar Documents

Publication Publication Date Title
AU2003260002B2 (en) Synthesis of epothilones, intermediates thereto, analogues and uses thereof
EP0918776B1 (fr) Synthese totale d'acylfulvenes antitumoraux
EP1040119B1 (fr) Analogues d'hemiasterline
US5206230A (en) Fluorine-containing vitamin D3 analogues and pharmaceutical composition containing the same
US20030176368A1 (en) Synthesis of epothilones, intermediates thereto and analogues thereof
US10000527B2 (en) 11-substituted bile acid derivatives, process for the preparation thereof and use of these compounds as medicaments
CA2647655C (fr) Nouveaux analogues substitues en c-1 de la pancratistatine et de la 7-desoxypancratistatine et leurs procedes de preparation
US8703792B2 (en) C-1 analogs of pancratistatin and 7-deoxypancratistatin and processes for their preparation
JP2009512662A (ja) 中間体、並びにかかる中間体を用いたエクチナサイジン５８３、５９７などのエクチナサイジン類の調製方法
EP0154185B1 (fr) Dérivés du calciférol
JP2020533374A (ja) 環状ペプチド抗生物質
EP0758316B1 (fr) Derives de borneol influant sur la polymerisation et la depolymerisation de la tubuline
Jackova et al. Total Synthesis and Bioactivity of ent-homospisulosine and N, O-diacetylhomoclavaminol A
TWI842251B (zh) 抗瘧疾藥劑
Gruszecka-Kowalik et al. Free-radical reactions of retronecine and heliotridine derivatives. The synthesis of (-)-supinidine
WO2007011629A2 (fr) Synthese et attribution stereochimique complete de psymberine/irciniastatine pour une application anti-tumorale
JP2004315373A (ja) 抗腫瘍活性および血管新生阻害活性を有する化合物、ならびにその製造方法
US20160002193A1 (en) Anticancer compounds and process for the preparation thereof
JP2000229977A (ja) トリデカノリド誘導体及び抗癌剤
US20040235939A1 (en) Synthesis of peloruside a and analogs thereof for use as antitumor agents
EP2493885B1 (fr) Molecules polyketides comme agents anticancereux
US7153885B2 (en) Stolonoxides
KR20250068745A (ko) 글루코코르티코이드 수용체 효능제
JP2026505889A (ja) Ｎｍｄ３の小分子モジュレーターとしてのポルチミンａ及びその類縁体の全合成
US20160362371A1 (en) Novel tricyclic compounds and preparation thereof

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20141030

H11 Ip right ceased following rejected request for revival

Free format text: ST27 STATUS EVENT CODE: T-6-6-H10-H11-H101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TIME LIMIT FOR REVERSAL EXPIRED

Effective date: 20240806